Submit

Login Login

Register Register

Home / Journals / OR / Online First / doi:10.32604/or.2026.076157
Journal Menu
Special Issues
Table of Content

All issues

Online First

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

Past Issues

Open Access

REVIEW

AI-Guided Discovery of Oncogenic Signaling Crosstalk in Tumor Progression and Drug Resistance

Edward Sutanto1, Rinni Sutanto2, Sara Velichkovikj3, Nikola Hadzi-Petrushev4, Mitko Mladenov4, Dimiter Avtanski5,6,7, Radoslav Stojchevski5,6,8,*
1 CUNY School of Medicine, The City College of New York, New York, NY, USA
2 New York Institute of Technology College of Osteopathic Medicine, Glen Head, NY, USA
3 Office of Clinical Research, Lenox Hill Hospital, Northwell Health, New York, NY, USA
4 Faculty of Natural Sciences and Mathematics, Institute of Biology, Ss. Cyril and Methodius University, Skopje, North Macedonia
5 Friedman Diabetes Institute, Lenox Hill Hospital, Northwell Health, New York, NY, USA
6 Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA
7 Institute of Bioelectronic Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, USA
8 Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, USA
* Corresponding Author: Radoslav Stojchevski. Email: email

Oncology Research https://doi.org/10.32604/or.2026.076157

Received 15 November 2025; Accepted 11 February 2026; Published online 03 March 2026

Abstract

The rapid growth and accessibility of artificial intelligence (AI) and machine learning (ML) have opened many avenues to revolutionize biomedical research, particularly in oncogenesis. Oncogenesis is a hallmark process in the development of cancer, involving the amplification of proto-oncogenes and the subsequent dysregulation of molecular signaling networks. These pathways—including the RAS/RAF/MEK/ERK, PI3K-AKT, JAK-STAT, TGF-β/Smad, Wnt/β-Catenin, and Notch cascades—have been studied extensively in isolation, with major strides achieved in understanding how they drive cancer. However, there are still many considerations regarding how these networks interact. Ongoing studies show that crosstalk among these pathways occurs through feedback loops, shared intermediates, and compensatory activation, creating a complex network that enables tumor cells to adapt and metastasize. New developments in AI and ML have enabled modeling and prediction of these interactions for pathway discovery, mapping oncogenic crosstalk, predicting drug resistance and therapeutic responses, and complex data analysis. Novel technologies such as feature selection algorithms and convolutional neural networks have demonstrated immense translational potential to bridge computational predictions in cancer genomics with clinical applications. Similar models have also proven useful for learning from genomic datasets and reducing multidimensionality in heterogeneous multiomics data. As current AI/ML approaches continue to develop, it is also important to consider the limitations of batch effects, model generalizability, and potential bias in training datasets. This review aims to integrate the most recent AI and ML applications in uncovering the hidden interactions within oncogenic networks that drive tumorigenesis, heterogeneity, and resistance to therapies. Moreover, this review aims to synthesize the functionality of emerging computational methods that elucidate these insights, as well as the transformative implications of AI-guided systems biology on precision oncology and combinatorial therapies.

Keywords

Artificial intelligence; machine learning; oncogenic signaling pathways; neural networks; tumor progression; drug resistance

  • 365

    View

  • 42

    Download

  • 0

    Like

Related articles
Copyright© 2026 Tech Science Press
© 1997-2026 TSP (Henderson, USA) unless otherwise stated

Share Link